ImmunityBio (IBRX) said Wednesday it has entered into a collaboration and supply agreement with BeiGene to conduct a phase 3 clinical trial combining BeiGene's tislelizumab and ImmunityBio's Anktiva as a potential therapy for the advanced or metastatic non-small cell lung cancer in patients who have acquired resistance to immune checkpoint inhibitors therapy.
Financial terms of the collaboration weren't disclosed.
ImmunityBio said it will conduct the confirmatory phase 3 trial across multiple sites and among 462 participants.
The primary endpoint of the study is overall survival, while secondary endpoints include disease control rate, progression-free survival, objective response rate, and safety, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。